Zhongnan Hospital

This study tests a chemotherapy regimen called FULIRI combined with targeted drugs (bevacizumab or cetuximab) as a first treatment for colorectal cancer that has spread to the liver. The goal is to shrink the liver tumors enough so that they can be surgically removed or treated w…

This study tests a combination of two drugs, Utidelone and Toripalimab, in people with recurrent or metastatic cervical cancer that has stopped responding to standard treatments. The goal is to see if the treatment can shrink or eliminate tumors and to check for side effects. Abo…

This study tests whether adding an immunotherapy drug (QL1706) to standard chemoradiation can improve outcomes for people with locally advanced rectal cancer. About 108 participants will be randomly assigned to receive either the standard treatment or the standard treatment plus …

This study will test a new imaging agent called 68Ga-B6FA-01, which targets two different markers on cancer cells and their surroundings. The goal is to see if this probe can improve PET/CT scans for diagnosing and staging solid tumors. About 100 adults with newly diagnosed or re…

This study tests a new imaging agent called 68Ga-SFB6-ZN01 that attaches to a protein found on many cancer cells but rarely on healthy cells. About 98 adults with known or suspected cancer will receive one injection and have a PET/CT scan. The goal is to see if the agent is safe …

This study tests a gentle, non-invasive brain stimulation method called Temporal Interference Stimulation (TIS) to see if it can improve movement in people with Parkinson's disease. Researchers will enroll 24 adults with mild to moderate Parkinson's who respond well to standard m…